• Pfizer’s Q2 2026 earnings call drew CEO Albert Bourla, CFO David Denton, incoming interim CFO Cecile Guegan, Chief Oncology Officer Chris Boshoff.
• Revenue guidance midpoint lifted by $500 million to a $60.5 billion-$62.5 billion range; COVID-19 revenue view cut to about $4 billion.
• Q2 revenue totaled $15 billion; adjusted diluted EPS was $0.77; adjusted diluted EPS guidance held at $2.80-$3 despite a $0.10 Innovent charge.
• Expanded cost programs targeted about $2.5 billion net savings in 2027-2029; total net savings expected about $9.7 billion through 2029.
• Management highlighted Padcev momentum, noting Q2 growth above 20% with la/mUC new patient share above 60%; growth expected to moderate as penetration rises.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.